<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study aims for the presentation of the first reported case of adalimumab-associated <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) and review of the literature on adalimumab-induced <z:hpo ids='HP_0002633'>vasculitis</z:hpo> and APS </plain></SENT>
<SENT sid="1" pm="."><plain>A case of APS associated with adalimumab use in a 67-year-old woman is reported </plain></SENT>
<SENT sid="2" pm="."><plain>The English medical literature was reviewed for antitumor <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF) agents and their association with APS and <z:hpo ids='HP_0002633'>vasculitis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Adalimumab is a fully humanized monoclonal antibody targeted against TNF alpha that is widely used in the treatment of <z:hpo ids='HP_0005681'>rheumatoid arthritis, juvenile</z:hpo> idiopathic <z:hpo ids='HP_0001369'>arthritis</z:hpo>, <z:e sem="disease" ids="C0038013" disease_type="Disease or Syndrome" abbrv="">ankylosing spondylitis</z:e>, psoriatic <z:hpo ids='HP_0001369'>arthritis</z:hpo>, <z:hpo ids='HP_0003765'>psoriasis</z:hpo>, and <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Literature review reveals several cases of anti-TNF-induced <z:hpo ids='HP_0002633'>vasculitis</z:hpo> including cases associated with adalimumab </plain></SENT>
<SENT sid="5" pm="."><plain>We report the first case of adalimumab-induced APS in a 67-year-old woman who developed APS and <z:hpo ids='HP_0002633'>vasculitis</z:hpo> associated with de novo positive anti-<z:chebi fb="0" ids="28494">cardiolipin</z:chebi> (aCL) antibody following the third dose of adalimumab therapy for the treatment of <z:e sem="disease" ids="C0949691" disease_type="Disease or Syndrome" abbrv="SPDA1">spondyloarthropathy</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>This is the first case demonstrating that a short course of adalimumab therapy may induce immunoglobulin M aCL autoantibodies leading to APS </plain></SENT>
<SENT sid="7" pm="."><plain>With the growing use of anti-TNF medications in immune-mediated and <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory diseases</z:e>, adalimumab and other anti-TNF medications should be considered as a possible explanation for APS </plain></SENT>
</text></document>